Objectives: To measure the uptake of antenatal HIV testing and determine its relation to risk of HIV and to screening practices. Design: Multicentre prospective questionnaire study.
Introduction
Antiretroviral therapy 1 and avoidance of breastfeeding 2 can reduce the risk of mother to child transmission of HIV from 25-30% to 5-8%. 3 4 In the United Kingdom, women who know their HIV status are increasingly taking up these interventions. 5 Despite national guidelines recommending that antenatal HIV testing should be offered to all women in areas of higher prevalence such as London, 6 in 1995 only 13 (39%) of the 33 London maternity units had a policy of offering testing to all pregnant women. 7 Nationally, detection of previously undiagnosed HIV infection in pregnancy has remained below 10%. 8 This study reports the offer and uptake of antenatal HIV testing in six London maternity units and examines how these are related to maternal risk of exposure to HIV and screening practices.
Methods
Six inner London maternity units with high HIV seroprevalence participated in the study. All had a "universal offer" policy, but implementation varied between units (see table 1 ). Within each unit, data on demographic and obstetric factors, including risk factors for HIV infection, were collected by questionnaire over a 12 month period during 1995 and 1996. Data on the number of women booking for antenatal care from each unit were collected and checked with laboratory data on number of samples sent for rubella antibody testing.
Data were analysed with univariate and multivariate logistic regression models controlling for hospital, risk category, ethnic group, place of booking interview, age, whether HIV was discussed and testing offered, and the interaction between hospital and risk category. Risk category included data on risks disclosed during the antenatal interview, and the categories "black African" and "partner black African," derived from self report of ethnic group and country of birth. The category "exposed in Africa" included any women born in Africa and those who gave their ethnic group as black African.
Results
One unit was excluded from the analysis (unit F) because only 17% of forms were returned, making calculation of uptake impossible. In the remaining five units, 21 247 women were booked for antenatal care over the period and 18 791 forms were returned (response rate of 88%, range 81-100%) (table 1) . Uptake of testing ranged from 3.4% to 51.2% (overall mean 22.9%). With the exception of unit C, where uptake increased from 22.9% to 33.6%, no significant trends were observed over the 12 month study period. The detection of previously undiagnosed HIV infection during pregnancy (based on unlinked anonymous surveys) ranged from 4.9% to 60% (23% overall) and increased in parallel with uptake (table 1) .
Overall, maternity unit had the greatest influence on uptake of testing ( 2 = 2907, df = 4, P < 0.0001). Length of gestation, the woman's fluency in English, whether she was seen alone or not, or booked in hospital or the community had little or no effect (data not shown). Among women with whom discussion about HIV transmission had taken place, uptake was higher by a factor of 2.1 (95% confidence interval 1.9 to 2.4) after other factors were controlled for, but in 23% of booking interviews no such discussion was reported.
Uptake of HIV testing was significantly higher among the 7% of women who disclosed a risk factor during the antenatal interview. Women who believed their partner was at risk ("partner other risk") or that Papers they were at risk ("other risk") had the highest uptakes, often citing occupational exposure or multiple partners (table 2) . Those disclosing intravenous drug use also had higher uptake. Those who had been exposed in Africa and those who had a partner who was black African had the lowest uptakes. Among those not disclosing risk there were strong ethnic differences, uptake being lowest (9%) in women of South Asian ethnic origin and highest (33%) in women of Mediterranean or Latin American origin.
The relation between risk category and uptake of testing varied considerably among units after other factors were controlled for ( 2 = 223, df = 36, P < 0.0001). The greatest difference in uptake between risk categories was observed in units with the lowest uptake of testing. For example, the greatest difference (56-fold relative uptake) was observed between "partner intravenous drug user" and "no disclosed risk: other" in unit A, which had the lowest overall uptake (3.4%); conversely, the smallest difference (1.4-fold) was observed between "partner other risk" and "no disclosed risk: other" in unit E, which had the highest overall uptake.
The average time spent by midwives discussing HIV issues was 7 minutes (95% confidence interval 2 to 15 minutes). This was similar across units and among women accepting testing and those not accepting (7.4 v 6.8 minutes). No women in units D and E, 0.6% of women in unit B, 0.8% in unit C, and all women wanting a test (3.4%) in unit A saw a counsellor. The mean time taken by counsellors was 20 (3 to 45) minutes and was independent of whether a woman was tested.
Discussion
Uptake of testing by maternity unit In five major London maternity units with high rates of HIV infection, less than a quarter of women were tested. This compares with 73-99% uptake reported in France, Scandinavia, and the United States. 3 9 10 The large differences between units cannot be explained by time spent by midwives discussing HIV issues, which was similar in all units, but may be due to other differences in implementing a "universal offer" policy. Unit A, with the lowest uptake, was the only unit where all women wanting an HIV test had to see a counsellor *Composed from data on risks disclosed during antenatal interview and self reported ethnic group and country of birth. If a woman belonged to more than one risk category, she was assigned to the first category in the following hierarchy: woman intravenous drug user; exposed in Africa; woman other risk; partner intravenous drug user; partner black African; partner other risk; unknown risk; no disclosed risk. †Relative to uptake in risk category "No disclosed risk: other." ‡Of this group, 74% were white.
first. The largest differences in uptake by risk category also occurred in this unit but were not due to higher uptake among women known to be at higher risk (exposed in Africa or intravenous drug user), as might be expected with a selective policy. Instead, differences were due to higher uptake among those women (only 3% of the antenatal population) who regarded themselves or their partners as at risk. Unit A was in practice implementing an "on request" policy. In contrast, the highest overall uptake, in unit E, was associated with little variation across risk categories; this was the unit with the most "universal offer" policy.
Uptake among women exposed in Africa
Of particular concern, because of their much higher seroprevalence, 11 was the finding that uptake among women exposed in Africa or with partners exposed in Africa was no higher than among most women with no disclosed risk. It is unclear whether these women were unaware of their increased risk or, if aware, were unwilling to be tested or assumed they were being tested when they were not. 12 Midwives may also be reluctant to offer HIV testing to African women because of concerns about perceived discrimination.
Detection of previously undiagnosed HIV infection
Detection of previously undiagnosed infection was higher in units with higher uptake, but overall nearly 80% of previously undiagnosed infected women went through pregnancy without being tested, unaware of their status and unable to benefit from interventions to reduce transmission of HIV from mother to child. A major reason for universal rather than selective HIV testing in areas of higher prevalence is to ensure high uptake among women at highest risk. Unless a concerted effort is made to increase overall uptake to much higher levels than those in this study, it could be argued that it might be better to direct resources to improving uptake in black African women despite the problems of perceived discrimination. An analysis of economic factors to determine how decisions on screening strategies should be tailored to patterns of HIV seroprevalence and distribution of risk categories in different parts of the United Kingdom is being undertaken. This will inform policy and assist in defining appropriate new strategies in London and in areas of low or intermediate seroprevalence outside London. Routine audit of HIV testing uptake, which in 1995 was lacking in all units, 7 is a prerequisite for the routine evaluation of urgently required new approaches to antenatal HIV testing.
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